Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
Pexidartinib mogelijk behandeloptie bij gevorderde tenosynoviale reusceltumoren
nov 2019 | Overig